Ketamine as an anesthetic and antidepressant: A review of clinical evidence
DOI:
https://doi.org/10.33448/rsd-v14i12.50391Keywords:
Treatment-resistant depression, Ketamine, Antidepressants.Abstract
Ketamine, traditionally used as a dissociative anesthetic, has emerged as a rapid-onset therapeutic alternative in the treatment of depressive disorders, especially in treatment-resistant cases. The objective of this study was to analyze the clinical evidence regarding the use of ketamine as both an anesthetic and an antidepressant. This is a systematic review of the literature conducted through the Virtual Health Library (VHL), using the descriptors “ketamine” AND (“depression” OR “depressive disorder” OR “major depressive disorder” OR “treatment-resistant depressive disorder”). A total of 122 publications were identified, of which 10 randomized controlled trials met the inclusion criteria. The studies demonstrate that ketamine promotes a rapid reduction in depressive symptoms, with significant effects observed within up to two hours after administration, including a decrease in suicidal ideation. Its mechanism of action involves glutamatergic modulation via NMDA receptor antagonism, promoting neuroplasticity and synaptic restoration. Additionally, ketamine presents few adverse cognitive effects and greater ease of implementation when compared to electroconvulsive therapy. However, variables such as the number of previous therapeutic failures and greater symptom severity may limit clinical response, reinforcing the need for individualized assessment. It is concluded that ketamine is an effective and rapid alternative for treatment-resistant depression, although standardization of protocols, long-term safety studies, and more robust clinical eligibility criteria are still required.
References
Abdallah, C. G., et al. (2016). Ketamine and rapid-acting antidepressants: A window into a new neurobiology for mood disorders. Nature Reviews Neuroscience, 17(3), 137–151.
Aan Het Rot, M., et al. (2012). Ketamine for depression: Where do we go from here? Biological Psychiatry, 72(7), 537–547.
Berman, R. M., et al. (2000). Antidepressant effects of ketamine in depressed patients. Biological Psychiatry, 47(4), 351–354.
Coyle, C. M., & Laws, K. R. (2015). The use of ketamine as an antidepressant: A systematic review. Journal of Psychopharmacology, 29(12), 1139–1159.
Daly, E. J., et al. (2018). Efficacy and safety of intranasal esketamine. JAMA Psychiatry, 75(2), 139–148.
Fond, G., et al. (2021). Ketamine for treatment-resistant depression: A systematic review. Journal of Affective Disorders, 294, 688–700.
Grady, S. E., et al. (2017). Ketamine for the treatment of major depressive disorder. Mental Health Clinician, 7(1), 39–47.
Ionescu, D. F., et al. (2019). Rapid reduction in suicidal ideation after ketamine infusion. Depression and Anxiety, 36(7), 700–708.
Kishimoto, T., et al. (2016). Ketamine for depression: A systematic review and meta-analysis. The Lancet Psychiatry, 3(5), 435–444.
Krystal, J. H., et al. (2013). Ketamine and the future of rapid-acting antidepressants. Neuropsychopharmacology, 38(1), 211–223.
Li, N., et al. (2010). mTOR-dependent synapse formation underlies rapid antidepressant effects of NMDA antagonists. Science, 329(5994), 959–964.
McIntyre, R. S., et al. (2021). Synthesizing the clinical evidence for ketamine in depression. CNS Drugs, 35(3), 243–256.
Murrough, J. W., et al. (2013). Rapid and longer-term antidepressant effects of repeated ketamine infusions. Biological Psychiatry, 74(4), 250–256.
Newport, D. J., et al. (2015). Ketamine and other NMDA antagonists in depression. The American Journal of Psychiatry, 172(10), 950–966.
Papadimitropoulou, K., et al. (2020). Efficacy of ketamine in major depression: An updated review. Psychiatry Research, 290, 113–120.
Pereira, A. S. et al. (2018). Metodologia da pesquisa científica. [Free ebook]. Santa Maria. Editora da UFSM.
Price, R. B., et al. (2014). Ketamine and suicidal ideation: A meta-analysis. Depression and Anxiety, 31(10), 958–966.
Reinstatler, L., & Youssef, N. A. (2015). Ketamine as a potential treatment for suicidal ideation. Current Neuropharmacology, 13(5), 732–742.
Sanacora, G., Schatzberg, A. F., et al. (2017). A consensus statement on the use of ketamine in depression. JAMA Psychiatry, 74(4), 399–405.
Snyder, H. (2019). Literature review as a research methodology: An overview and guidelines. Journal of Business Research, Elsevier. 104(C), 333-9.
Wilkinson, S. T., et al. (2018). The effect of a single dose of intravenous ketamine on suicidal ideation. The American Journal of Psychiatry, 175(4), 327–335.
Zarate, C. A., et al. (2006). A randomized trial of an NMDA antagonist in treatment-resistant major depression. Archives of General Psychiatry, 63(8), 856–864.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Thiago Vaz de Andrade, Caio César Balthazar da Silveira Vidal, Luma Teles de Resende, Mylenna Menezes Leite Nascimento, Luana Teles de Resende
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
